Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1865137 | 1.00 | GCK (0.58) | GCKKMT2AEPHX1MEN1KCNH2 | |
| SCHEMBL2646260 | 0.99 | GCK (0.57) | GCKKMT2AEPHX1MEN1KCNH2 | |
| SCHEMBL2646180 | 0.99 | GCK (0.57) | GCKKMT2AEPHX1MEN1KCNH2 | |
| SCHEMBL1107388 | 0.89 | GCK (0.58) | GCKKMT2AEPHX1MEN1KCNH2 | |
| SCHEMBL2651394 | 0.88 | GCK (0.61) | GCK | |
| SCHEMBL2652176 | 0.88 | GCK (0.61) | GCK | |
| SCHEMBL2650823 | 0.87 | GCK (0.57) | GCKKMT2AEPHX1MEN1KCNH2 | |
| SCHEMBL2647881 | 0.87 | GCK (0.47) | GCKKMT2A | |
| SCHEMBL2667236 | 0.87 | GCK (0.57) | GCKKMT2AEPHX1KCNH2 | |
| SCHEMBL18677581 | 0.87 | GCK (0.46) | GCKKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318746-B2 | Nitrogen-containing five-membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8148412-B2 | e.g. {-[3-Cyclopentyl-2-(4-methane sulfonyl-phenyl)-propionylamino]-5-methyl-thiazol-4-yl}-acetic acid ethyl ester; antidiabetic and hypoglycemic agent; non-insulin dependent diabetis, obesity, impaired glucose tolerance, eating disorder, dyslipidemia, hyperlipidemia, hypertension | NOVO NORDISK A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-20110130402-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-06-02 | — | — | US | disclosed |
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20100330021-A1 | SUBSTITUTED (THIAZOL-2-YL)-AMIDE OR SULFONAMIDE AS GLYCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF TYPE 2 DIABETES | BEBERNITZ GREGORY RAYMOND | 2010-12-30 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-7812167-B2 | Substituted (thiazol-2-yl)-amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes | NOVARTIS, AG (CH) | 2010-10-12 | — | — | US | disclosed |
| CN-101805358-A | As glucokinase activating agents, can be used for treating (thiazol-2-yl) acid amides or the sulphonamide of the replacement of type II diabetes | NOVARTIS AG | 2010-08-18 | — | — | CN | disclosed |
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2149550-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-6433188-B1 | ANTIDIABETIC AGENTS | CORBETT WENDY LEA (US) | 2002-08-13 | — | — | US | disclosed |
| US-20020107396-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY LEA (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020103199-A1 | Fused heteroaromatic glucokinase activators | CORBETT WENDY LEA (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020103241-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-01 | — | — | US | disclosed |
| WO-2002046173-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
| CN-1349519-A | Glucokinase activators | HOFFMANN LA ROCHE (CH) | 2002-05-15 | — | — | CN | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103199-A1 | Fused heteroaromatic glucokinase activators | GCKR, GCK, GPR119 | GCK 2/4885KMT2A 3124/4885EPHX1 4748/4885 |
| US-20100130446-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND | GCKR, GCK, SLC5A1 | GCK 2/4885KMT2A 1144/4885EPHX1 3208/4885 |
| US-20100330021-A1 | SUBSTITUTED (THIAZOL-2-YL)-AMIDE OR SULFONAMIDE AS GLYCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF TYPE 2 DIABETES | GCKR, GCK, GPR119 | GCK 2/4885KMT2A 773/4885EPHX1 3195/4885 |
| US-20020107396-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | GCK 2/4885KMT2A 3124/4885EPHX1 4748/4885 |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885KMT2A 2763/4885EPHX1 4716/4885 |
| US-20110130402-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | GCK 1/4885KMT2A 3351/4885EPHX1 4501/4885 |
| US-20020103241-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | GCK 2/4885KMT2A 3124/4885EPHX1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.